The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Proton Pump Inhibitors for Gastric Acid Therapy Market Research Report 2025
Synopsis
Proton pump inhibitors (PPIs) reduce the production of acid by blocking the enzyme in the wall of the stomach that produces acid. Acid is necessary for the formation of most ulcers in the esophagus, stomach, and duodenum, and the reduction of acid with PPIs prevents ulcers and allows any ulcers that exist in the esophagus, stomach, and duodenum to heal.
Global Proton Pump Inhibitors for Gastric Acid Therapy market is projected to reach US$ 9299.2 million in 2029, increasing from US$ 11790 million in 2022, with the CAGR of -3.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Proton Pump Inhibitors for Gastric Acid Therapy market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Proton Pump Inhibitors for Gastric Acid Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Takeda
Pfizer
AstraZeneca
Bayer
Sun Pharma
Teva
Eisai Co.
Mylan
AOSAIKANG Pharma
Luoxin Pharma
LIVZON
Eastchina Pharma
Segment by Type
Dexlansoprazole
Esomeprazole
Lansoprazole
Omeprazole
Pantoprazole
Rabeprazole
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Proton Pump Inhibitors for Gastric Acid Therapy report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Proton pump inhibitors (PPIs) reduce the production of acid by blocking the enzyme in the wall of the stomach that produces acid. Acid is necessary for the formation of most ulcers in the esophagus, stomach, and duodenum, and the reduction of acid with PPIs prevents ulcers and allows any ulcers that exist in the esophagus, stomach, and duodenum to heal.
Global Proton Pump Inhibitors for Gastric Acid Therapy market is projected to reach US$ 9299.2 million in 2029, increasing from US$ 11790 million in 2022, with the CAGR of -3.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Proton Pump Inhibitors for Gastric Acid Therapy market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Proton Pump Inhibitors for Gastric Acid Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Takeda
Pfizer
AstraZeneca
Bayer
Sun Pharma
Teva
Eisai Co.
Mylan
AOSAIKANG Pharma
Luoxin Pharma
LIVZON
Eastchina Pharma
Segment by Type
Dexlansoprazole
Esomeprazole
Lansoprazole
Omeprazole
Pantoprazole
Rabeprazole
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Proton Pump Inhibitors for Gastric Acid Therapy report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Proton Pump Inhibitors for Gastric Acid Therapy Market Overview
1.1 Product Overview and Scope of Proton Pump Inhibitors for Gastric Acid Therapy
1.2 Proton Pump Inhibitors for Gastric Acid Therapy Segment by Type
1.2.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Market Value Comparison by Type (2023-2029)
1.2.2 Dexlansoprazole
1.2.3 Esomeprazole
1.2.4 Lansoprazole
1.2.5 Omeprazole
1.2.6 Pantoprazole
1.2.7 Rabeprazole
1.3 Proton Pump Inhibitors for Gastric Acid Therapy Segment by Application
1.3.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Global Proton Pump Inhibitors for Gastric Acid Therapy Market Size Estimates and Forecasts
1.4.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue 2018-2029
1.4.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales 2018-2029
1.4.3 Global Proton Pump Inhibitors for Gastric Acid Therapy Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Proton Pump Inhibitors for Gastric Acid Therapy Market Competition by Manufacturers
2.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales Market Share by Manufacturers (2018-2023)
2.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Proton Pump Inhibitors for Gastric Acid Therapy Average Price by Manufacturers (2018-2023)
2.4 Global Proton Pump Inhibitors for Gastric Acid Therapy Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Proton Pump Inhibitors for Gastric Acid Therapy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Proton Pump Inhibitors for Gastric Acid Therapy, Product Type & Application
2.7 Proton Pump Inhibitors for Gastric Acid Therapy Market Competitive Situation and Trends
2.7.1 Proton Pump Inhibitors for Gastric Acid Therapy Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Proton Pump Inhibitors for Gastric Acid Therapy Players Market Share by Revenue
2.7.3 Global Proton Pump Inhibitors for Gastric Acid Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Proton Pump Inhibitors for Gastric Acid Therapy Retrospective Market Scenario by Region
3.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Global Proton Pump Inhibitors for Gastric Acid Therapy Sales by Region: 2018-2029
3.2.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales by Region: 2018-2023
3.2.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales by Region: 2024-2029
3.3 Global Proton Pump Inhibitors for Gastric Acid Therapy Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Region: 2018-2029
3.3.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Region: 2018-2023
3.3.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Region: 2024-2029
3.4 North America Proton Pump Inhibitors for Gastric Acid Therapy Market Facts & Figures by Country
3.4.1 North America Proton Pump Inhibitors for Gastric Acid Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Proton Pump Inhibitors for Gastric Acid Therapy Sales by Country (2018-2029)
3.4.3 North America Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Proton Pump Inhibitors for Gastric Acid Therapy Market Facts & Figures by Country
3.5.1 Europe Proton Pump Inhibitors for Gastric Acid Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Proton Pump Inhibitors for Gastric Acid Therapy Sales by Country (2018-2029)
3.5.3 Europe Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Proton Pump Inhibitors for Gastric Acid Therapy Market Facts & Figures by Country
3.6.1 Asia Pacific Proton Pump Inhibitors for Gastric Acid Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Proton Pump Inhibitors for Gastric Acid Therapy Sales by Country (2018-2029)
3.6.3 Asia Pacific Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Proton Pump Inhibitors for Gastric Acid Therapy Market Facts & Figures by Country
3.7.1 Latin America Proton Pump Inhibitors for Gastric Acid Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Proton Pump Inhibitors for Gastric Acid Therapy Sales by Country (2018-2029)
3.7.3 Latin America Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Proton Pump Inhibitors for Gastric Acid Therapy Market Facts & Figures by Country
3.8.1 Middle East and Africa Proton Pump Inhibitors for Gastric Acid Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Proton Pump Inhibitors for Gastric Acid Therapy Sales by Country (2018-2029)
3.8.3 Middle East and Africa Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales by Type (2018-2029)
4.1.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales by Type (2018-2023)
4.1.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales by Type (2024-2029)
4.1.3 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales Market Share by Type (2018-2029)
4.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Type (2018-2029)
4.2.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Type (2018-2023)
4.2.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Type (2024-2029)
4.2.3 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue Market Share by Type (2018-2029)
4.3 Global Proton Pump Inhibitors for Gastric Acid Therapy Price by Type (2018-2029)
5 Segment by Application
5.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales by Application (2018-2029)
5.1.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales by Application (2018-2023)
5.1.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales by Application (2024-2029)
5.1.3 Global Proton Pump Inhibitors for Gastric Acid Therapy Sales Market Share by Application (2018-2029)
5.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Application (2018-2029)
5.2.1 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Application (2018-2023)
5.2.2 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue by Application (2024-2029)
5.2.3 Global Proton Pump Inhibitors for Gastric Acid Therapy Revenue Market Share by Application (2018-2029)
5.3 Global Proton Pump Inhibitors for Gastric Acid Therapy Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Takeda
6.1.1 Takeda Corporation Information
6.1.2 Takeda Description and Business Overview
6.1.3 Takeda Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Takeda Proton Pump Inhibitors for Gastric Acid Therapy Product Portfolio
6.1.5 Takeda Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Pfizer Proton Pump Inhibitors for Gastric Acid Therapy Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Corporation Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue and Gross Margin (2018-2023)
6.3.4 AstraZeneca Proton Pump Inhibitors for Gastric Acid Therapy Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Bayer
6.4.1 Bayer Corporation Information
6.4.2 Bayer Description and Business Overview
6.4.3 Bayer Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Bayer Proton Pump Inhibitors for Gastric Acid Therapy Product Portfolio
6.4.5 Bayer Recent Developments/Updates
6.5 Sun Pharma
6.5.1 Sun Pharma Corporation Information
6.5.2 Sun Pharma Description and Business Overview
6.5.3 Sun Pharma Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Sun Pharma Proton Pump Inhibitors for Gastric Acid Therapy Product Portfolio
6.5.5 Sun Pharma Recent Developments/Updates
6.6 Teva
6.6.1 Teva Corporation Information
6.6.2 Teva Description and Business Overview
6.6.3 Teva Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Teva Proton Pump Inhibitors for Gastric Acid Therapy Product Portfolio
6.6.5 Teva Recent Developments/Updates
6.7 Eisai Co.
6.6.1 Eisai Co. Corporation Information
6.6.2 Eisai Co. Description and Business Overview
6.6.3 Eisai Co. Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Eisai Co. Proton Pump Inhibitors for Gastric Acid Therapy Product Portfolio
6.7.5 Eisai Co. Recent Developments/Updates
6.8 Mylan
6.8.1 Mylan Corporation Information
6.8.2 Mylan Description and Business Overview
6.8.3 Mylan Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Mylan Proton Pump Inhibitors for Gastric Acid Therapy Product Portfolio
6.8.5 Mylan Recent Developments/Updates
6.9 AOSAIKANG Pharma
6.9.1 AOSAIKANG Pharma Corporation Information
6.9.2 AOSAIKANG Pharma Description and Business Overview
6.9.3 AOSAIKANG Pharma Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue and Gross Margin (2018-2023)
6.9.4 AOSAIKANG Pharma Proton Pump Inhibitors for Gastric Acid Therapy Product Portfolio
6.9.5 AOSAIKANG Pharma Recent Developments/Updates
6.10 Luoxin Pharma
6.10.1 Luoxin Pharma Corporation Information
6.10.2 Luoxin Pharma Description and Business Overview
6.10.3 Luoxin Pharma Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Luoxin Pharma Proton Pump Inhibitors for Gastric Acid Therapy Product Portfolio
6.10.5 Luoxin Pharma Recent Developments/Updates
6.11 LIVZON
6.11.1 LIVZON Corporation Information
6.11.2 LIVZON Proton Pump Inhibitors for Gastric Acid Therapy Description and Business Overview
6.11.3 LIVZON Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue and Gross Margin (2018-2023)
6.11.4 LIVZON Proton Pump Inhibitors for Gastric Acid Therapy Product Portfolio
6.11.5 LIVZON Recent Developments/Updates
6.12 Eastchina Pharma
6.12.1 Eastchina Pharma Corporation Information
6.12.2 Eastchina Pharma Proton Pump Inhibitors for Gastric Acid Therapy Description and Business Overview
6.12.3 Eastchina Pharma Proton Pump Inhibitors for Gastric Acid Therapy Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Eastchina Pharma Proton Pump Inhibitors for Gastric Acid Therapy Product Portfolio
6.12.5 Eastchina Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Proton Pump Inhibitors for Gastric Acid Therapy Industry Chain Analysis
7.2 Proton Pump Inhibitors for Gastric Acid Therapy Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Proton Pump Inhibitors for Gastric Acid Therapy Production Mode & Process
7.4 Proton Pump Inhibitors for Gastric Acid Therapy Sales and Marketing
7.4.1 Proton Pump Inhibitors for Gastric Acid Therapy Sales Channels
7.4.2 Proton Pump Inhibitors for Gastric Acid Therapy Distributors
7.5 Proton Pump Inhibitors for Gastric Acid Therapy Customers
8 Proton Pump Inhibitors for Gastric Acid Therapy Market Dynamics
8.1 Proton Pump Inhibitors for Gastric Acid Therapy Industry Trends
8.2 Proton Pump Inhibitors for Gastric Acid Therapy Market Drivers
8.3 Proton Pump Inhibitors for Gastric Acid Therapy Market Challenges
8.4 Proton Pump Inhibitors for Gastric Acid Therapy Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
